PT3593817T - Composição para a utilização na prevenção ou supressão da miopia - Google Patents

Composição para a utilização na prevenção ou supressão da miopia

Info

Publication number
PT3593817T
PT3593817T PT187646526T PT18764652T PT3593817T PT 3593817 T PT3593817 T PT 3593817T PT 187646526 T PT187646526 T PT 187646526T PT 18764652 T PT18764652 T PT 18764652T PT 3593817 T PT3593817 T PT 3593817T
Authority
PT
Portugal
Prior art keywords
myopia
murine
preventing
endoplasmic reticulum
reticulum stress
Prior art date
Application number
PT187646526T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Tsubota Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsubota Lab Inc filed Critical Tsubota Lab Inc
Publication of PT3593817T publication Critical patent/PT3593817T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/02—Breeding vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G02—OPTICS
    • G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
    • G02C7/00—Optical parts
    • G02C7/02—Lenses; Lens systems ; Methods of designing lenses
    • G02C7/06—Lenses; Lens systems ; Methods of designing lenses bifocal; multifocal ; progressive
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/30—Animals modified by surgical methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
PT187646526T 2017-03-06 2018-03-06 Composição para a utilização na prevenção ou supressão da miopia PT3593817T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017041349 2017-03-06

Publications (1)

Publication Number Publication Date
PT3593817T true PT3593817T (pt) 2024-12-17

Family

ID=63448602

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187646526T PT3593817T (pt) 2017-03-06 2018-03-06 Composição para a utilização na prevenção ou supressão da miopia

Country Status (13)

Country Link
US (2) US12478597B2 (enExample)
EP (1) EP3593817B1 (enExample)
JP (6) JP6637217B2 (enExample)
KR (1) KR102680012B1 (enExample)
CN (3) CN110392579B (enExample)
DK (1) DK3593817T3 (enExample)
ES (1) ES2997337T3 (enExample)
FI (1) FI3593817T3 (enExample)
HR (1) HRP20241734T1 (enExample)
HU (1) HUE069999T2 (enExample)
PL (1) PL3593817T3 (enExample)
PT (1) PT3593817T (enExample)
WO (1) WO2018164113A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202106216SA (en) * 2018-12-18 2021-07-29 Santen Pharmaceutical Co Ltd Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
AU2019405587A1 (en) 2018-12-18 2021-07-01 Santen Pharmaceutical Co., Ltd. Agent containing 4-phenylbutyrate, for preventing or treating presbyopia
JP7608707B2 (ja) * 2019-02-25 2025-01-07 株式会社坪田ラボ 近視進行抑制剤、機能性食品及び眼科用組成物
WO2020185673A1 (en) * 2019-03-08 2020-09-17 The Regents Of The University Of California Compositions and methods for treating respiratory insufficiency
KR20230051155A (ko) * 2020-06-11 2023-04-17 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 베르베리다세아엔 알칼로이드인 베르베린 및 이의 유도체를 이용한 근시의 예방 및 치료를 위한 방법 및 조성물
IL303511A (en) * 2020-12-11 2023-08-01 Tsubota Lab Inc Eye drops for the treatment of scleral thinning and a filtration method for a therapeutic agent of scleral thinning
EP4257147A4 (en) * 2020-12-11 2024-11-06 Tsubota Laboratory, Inc. EYE DROPS FOR INHIBITING MYOPIA PROGRESSION IN CHILDREN AND SCREENING METHOD FOR MYOPIA PROGRESSION INHIBITOR IN CHILDREN
CN112970666B (zh) * 2021-02-04 2023-02-03 复旦大学附属眼耳鼻喉科医院 一种简便式动物近视诱导装置及制作方法
JP2024069730A (ja) * 2021-03-16 2024-05-22 慶應義塾 網膜変性抑制用組成物
TW202340723A (zh) * 2022-01-25 2023-10-16 日商坪田實驗室股份有限公司 藉由藥劑點眼而導致之近視誘導模型
JPWO2023182480A1 (enExample) 2022-03-25 2023-09-28
EP4516305A1 (en) * 2022-04-26 2025-03-05 Tsubota Laboratory, Inc. Method and composition for preventing or treating myopia
WO2024048697A1 (ja) * 2022-08-31 2024-03-07 国立大学法人京都大学 化合物、小胞体ストレス抑制剤、医薬品、眼科用剤、点眼薬、組成物、化合物の製造方法
CN115777618B (zh) * 2022-11-14 2025-07-08 首都医科大学附属北京同仁医院 一种病理性近视动物模型的构建方法及用途
CN116267712B (zh) * 2023-02-23 2024-08-06 温州医科大学 一种近视眼动物模型的构建方法及其应用
WO2024203727A1 (ja) * 2023-03-24 2024-10-03 株式会社坪田ラボ 水性組成物
CN116918764B (zh) * 2023-08-28 2025-11-28 河南省儿童医院郑州儿童医院 一种豚鼠近视模型的构建方法
JP7781461B2 (ja) * 2023-10-25 2025-12-08 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
WO2025089394A1 (ja) * 2023-10-25 2025-05-01 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
CN117797133A (zh) * 2023-12-29 2024-04-02 上海交通大学医学院附属仁济医院 内质网应激抑制剂isrib在制备胎儿宫内生长受限药物中的应用
WO2025182819A1 (ja) * 2024-02-29 2025-09-04 慶應義塾 動物モデルの作製方法
CN120392754B (zh) * 2025-07-02 2025-09-09 深圳市中佳生物医疗科技有限公司 化合物在制备增强造血干细胞代谢活性、治疗异染性脑白质营养不良的产品中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3066561B2 (ja) 1993-10-07 2000-07-17 武田薬品工業株式会社 近視予防・治療剤
JPH09315954A (ja) 1996-05-30 1997-12-09 Kita:Kk 眼科手術後の眼組織混濁防止剤。
JP2003520228A (ja) 2000-01-18 2003-07-02 バリー フォージ ファーマスーティカルズ インコーポレイテッド 眼の成長及びニコチン性アンタゴニスト
CN1191074C (zh) * 2002-09-18 2005-03-02 王力 熊胆粉滴眼液及其制备方法
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
CN101056656A (zh) * 2004-09-15 2007-10-17 哈佛大学校长及研究员协会 在治疗肥胖症和糖尿病中降低er应力
US20060073213A1 (en) * 2004-09-15 2006-04-06 Hotamisligil Gokhan S Reducing ER stress in the treatment of obesity and diabetes
JPWO2010010702A1 (ja) * 2008-07-24 2012-01-05 国立大学法人大阪大学 軸性近視の予防または治療剤
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
CA2794153C (en) * 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
US8962686B2 (en) 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
KR102011947B1 (ko) * 2011-01-14 2019-08-19 유니버시티 오브 워싱턴 눈 길이 관련 질환을 진단 및 치료하는 방법
WO2013025840A1 (en) * 2011-08-15 2013-02-21 Massachusetts Eye And Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
GB201217296D0 (en) * 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
WO2015056180A1 (en) * 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
ES2847755T3 (es) 2013-10-31 2021-08-03 Kyoto Prefectural Public Univ Corp Fármaco terapéutico que comprende un inhibidor de la señal de TGF-beta para enfermedades relacionadas con la muerte celular del retículo endoplásmico en el endotelio corneal
WO2016171282A1 (ja) * 2015-04-24 2016-10-27 学校法人慶應義塾 近視予防剤及び近視進行抑制剤

Also Published As

Publication number Publication date
JP6856275B2 (ja) 2021-04-07
KR20190126365A (ko) 2019-11-11
US12478597B2 (en) 2025-11-25
DK3593817T3 (da) 2024-11-25
FI3593817T3 (fi) 2025-02-05
JP2023017050A (ja) 2023-02-02
CN115645535B (zh) 2024-07-09
ES2997337T3 (en) 2025-02-17
JPWO2018164113A1 (ja) 2019-06-27
JP2025013575A (ja) 2025-01-24
US20240210736A1 (en) 2024-06-27
JP2024026709A (ja) 2024-02-28
PL3593817T3 (pl) 2025-03-31
CN115645536A (zh) 2023-01-31
JP6637217B2 (ja) 2020-01-29
JP7236753B2 (ja) 2023-03-10
HRP20241734T1 (hr) 2025-02-28
JP2020023574A (ja) 2020-02-13
CN115645535A (zh) 2023-01-31
KR102680012B1 (ko) 2024-06-28
EP3593817A4 (en) 2021-04-07
HUE069999T2 (hu) 2025-04-28
US20200150457A1 (en) 2020-05-14
EP3593817B1 (en) 2024-11-13
JP7424676B2 (ja) 2024-01-30
CN110392579A (zh) 2019-10-29
CN110392579B (zh) 2022-11-08
EP3593817A1 (en) 2020-01-15
JP2021091731A (ja) 2021-06-17
WO2018164113A1 (ja) 2018-09-13

Similar Documents

Publication Publication Date Title
PT3593817T (pt) Composição para a utilização na prevenção ou supressão da miopia
CA191347S (en) Chair
SG11202103033WA (en) Compositions and methods for the treatment of presbyopia
GB2591554B (en) Composiitons and methods and uses relating thereto
PL3626237T3 (pl) Kompozycje do zapobiegania krótkowzroczności oraz żywność funkcjonalna
IL292627A (en) Regulatory transcription elements
CA188496S (en) Combination eyewash and faucet
DK3992523T3 (en) Scenelampe med trådløst strømsignaltransmissionssystem
CA201895S (en) Autoinjector
GB2589437B (en) Circuitry and methods
SI3701956T1 (sl) Profilaktično in/ali terapevtsko sredstvo za demenco
CA206019S (en) Autoinjector
PT3319950T (pt) Diaminas primárias vicinais associadas com motivos quelantes de metais e/ou de radicais livres, e ativas contra o stress carbonilo e oxidativo, e seu uso
EP3797179C0 (en) NEW AUSTENITIC ALLOY
CA192531S (en) Coffin
CA209639S (en) Safe
GB2596773B (en) Beverage ingredient treatment method and related packaged ingredient
ZA202007278B (en) Protective member
CA190907S (en) Chair
CA189981S (en) Chair
CA187999S (en) Chair
CA187527S (en) Chair
CA187529S (en) Chair
CA187525S (en) Chair
CA187532S (en) Chair